
Michael Manns

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4543271/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C. Journal of Infectious Diseases, 2022, 226, 441-452.	1.9	18
2	Surgical Procedures in Patients Awaiting Liver Transplantation: Complications and Impact on the Liver Function. Journal of Clinical and Experimental Hepatology, 2022, 12, 68-79.	0.4	1
3	The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis. Hepatology Communications, 2022, 6, 320-333.	2.0	21
4	HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatology Communications, 2022, 6, 480-495.	2.0	15
5	Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS. Hepatology Communications, 2022, 6, 621-632.	2.0	2
6	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	3.6	16
7	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. Clinical Gastroenterology and Hepatology, 2022, 20, 438-446.	2.4	10
8	The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	6.3	257
9	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. Journal of Hepatology, 2022, 76, 841-849.	1.8	64
10	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	1.8	21
11	The biliary microbiome in ischaemicâ€ŧype biliary lesions can be shaped by stenting but is resilient to antibiotic treatment. Liver International, 2022, 42, 1070-1083.	1.9	4
12	Nosocomial infections in female compared with male patients with decompensated liver cirrhosis. Scientific Reports, 2022, 12, 3285.	1.6	0
13	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. Journal of Viral Hepatitis, 2022, 29, 536-542.	1.0	14
14	The curing regimens of HCV: A SWOT analysis. Antiviral Therapy, 2022, 27, 135965352110726.	0.6	6
15	Breakthroughs in hepatitis C research: from discovery to cure. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 533-550.	8.2	62
16	Microbiota-associated Risk Factors for <i>Clostridioides difficile</i> Acquisition in Hospitalized Patients: A Prospective, Multicentric Study. Clinical Infectious Diseases, 2021, 73, e2625-e2634.	2.9	6
17	MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 122-134.	1.8	109
18	Transcriptome Profiling Identifies TIGIT as a Marker of T ell Exhaustion in Liver Cancer. Hepatology, 2021, 73, 1399-1418.	3.6	61

#	Article	IF	CITATIONS
19	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1248-1257.	2.4	25
20	Fully automated detection of primary sclerosing cholangitis (PSC)-compatible bile duct changes based on 3D magnetic resonance cholangiopancreatography using machine learning. European Radiology, 2021, 31, 2482-2489.	2.3	7
21	CKâ€18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. Liver International, 2021, 41, 123-127.	1.9	3
22	A transient early HBVâ€DNA increase during PEGâ€IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDVâ€RNA and HBsAg reduction. Journal of Viral Hepatitis, 2021, 28, 410-419.	1.0	5
23	Residual low HDV viraemia is associated HDV RNA relapse after PEGâ€IFNaâ€based antiviral treatment of hepatitis delta: Results from the HIDITâ€II study. Liver International, 2021, 41, 295-299.	1.9	18
24	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. Journal of Hepatology, 2021, 74, 1053-1063.	1.8	68
25	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	1.8	149
26	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. Journal of Hepatology, 2021, 74, 321-329.	1.8	55
27	Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis. Biomedicines, 2021, 9, 58.	1.4	6
28	P174â€Exploration of urinary peptides in hepatocellular carcinoma. , 2021, , .		0
29	Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer. Oncolmmunology, 2021, 10, 1874159.	2.1	9
30	Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. Journal of Autoimmunity, 2021, 117, 102591.	3.0	32
31	Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. Biomedicines, 2021, 9, 353.	1.4	18
32	Significant compartmentâ€specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. Liver International, 2021, 41, 1815-1823.	1.9	4
33	Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology, 2021, 74, 72-82.	3.6	19
34	Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration. Cells, 2021, 10, 1471.	1.8	9
35	Scent dog identification of SARS-CoV-2 infections in different body fluids. BMC Infectious Diseases, 2021, 21, 707.	1.3	24
36	Primary sclerosing cholangitis with moderately elevated serumâ€igG4 – characterization and outcome of a distinct variant phenotype. Liver International, 2021, , .	1.9	1

#	Article	IF	CITATIONS
37	Pathophysiological Implications of Urinary Peptides in Hepatocellular Carcinoma. Cancers, 2021, 13, 3786.	1.7	7
38	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). Journal of Hepatology, 2021, 75, 1346-1354.	1.8	69
39	Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R). Biomedicines, 2021, 9, 1495.	1.4	7
40	Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. European Journal of Gastroenterology and Hepatology, 2021, 32, 223-229.	0.8	3
41	Discrimination of SARS-CoV-2 Infections From Other Viral Respiratory Infections by Scent Detection Dogs. Frontiers in Medicine, 2021, 8, 749588.	1.2	17
42	High-Molecular-Weight Fractions of Spruce and Eucalyptus Lignin as a Perspective Nanoparticle-Based Platform for a Therapy Delivery in Liver Cancer. Frontiers in Bioengineering and Biotechnology, 2021, 9, 817768.	2.0	11
43	Adjuvant Therapy with Budesonide Post-Kasai Reduces the Need for Liver Transplantation in Biliary Atresia. Journal of Clinical Medicine, 2021, 10, 5758.	1.0	3
44	Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. Clinical Gastroenterology and Hepatology, 2020, 18, 1609-1617.e4.	2.4	25
45	Quantitation of large, middle and small hepatitis B surface proteins in HBeAgâ€positive patients treated with peginterferon alfaâ€2a. Liver International, 2020, 40, 324-332.	1.9	13
46	Nonocclusive Mesenteric Ischemia and Interventional Local Vasodilatory Therapy: A Meta-Analysis and Systematic Review of the Literature. Journal of Intensive Care Medicine, 2020, 35, 128-139.	1.3	13
47	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	3.6	42
48	Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma. Journal of Biomedical Science, 2020, 27, 13.	2.6	19
49	Letter: a 5â€year longâ€ŧerm followâ€up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. Alimentary Pharmacology and Therapeutics, 2020, 51, 194-195.	1.9	8
50	Autoimmune hepatitis induction can occur in the liver. Liver International, 2020, 40, 377-381.	1.9	10
51	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. JHEP Reports, 2020, 2, 100060.	2.6	9
52	ExÂVivo/InÂvivo Gene Editing in Hepatocytes Using "All-in-One―CRISPR-Adeno-Associated Virus Vectors with a Self-Linearizing Repair Template. IScience, 2020, 23, 100764.	1.9	33
53	DSA Are Associated With More Graft Injury, More Fibrosis, and Upregulation of Rejection-associated Transcripts in Subclinical Rejection. Transplantation, 2020, 104, 551-561.	0.5	32
54	Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells. Gut, 2020, 69, 1104-1115.	6.1	37

#	Article	IF	CITATIONS
55	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology, 2020, 72, 671-722.	3.6	473
56	Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Journal of Hepatology, 2020, 73, 1496-1506.	1.8	55
57	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
58	MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis. Hepatology, 2020, 72, 1378-1393.	3.6	29
59	Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre study. EBioMedicine, 2020, 62, 103083.	2.7	10
60	Scent dog identification of samples from COVID-19 patients – a pilot study. BMC Infectious Diseases, 2020, 20, 536.	1.3	132
61	Tenâ€year followâ€up of a randomized controlled clinical trial in chronic hepatitis delta. Journal of Viral Hepatitis, 2020, 27, 1359-1368.	1.0	47
62	Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies. Scientific Reports, 2020, 10, 14242.	1.6	29
63	Sequential systemic treatment in patients with hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2020, 52, 205-212.	1.9	17
64	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. Liver International, 2020, 40, 2164-2171.	1.9	16
65	Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). European Journal of Radiology, 2020, 129, 109101.	1.2	13
66	Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3003-3012.	1.2	18
67	Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Metaâ€Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology, 2020, 72, 753-769.	3.6	30
68	Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	13
69	Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury. Liver International, 2020, 40, 1225-1238.	1.9	16
70	Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites. United European Gastroenterology Journal, 2020, 8, 567-576.	1.6	13
71	Overcoming fragmentation of health research in Europe: lessons from COVID-19. Lancet, The, 2020, 395, 1970-1971.	6.3	14
72	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study. Journal of Hepatology, 2020, 73, 696-699.	1.8	39

#	Article	IF	CITATIONS
73	Therapeutic plasma exchange in acute on chronic liver failure. Journal of Clinical Apheresis, 2020, 35, 316-327.	0.7	10
74	Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites. PLoS ONE, 2020, 15, e0235199.	1.1	7
75	The future of autoimmune liver diseases – Understanding pathogenesis and improving morbidity and mortality. Liver International, 2020, 40, 149-153.	1.9	22
76	Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy. Open Forum Infectious Diseases, 2020, 7, ofaa040.	0.4	17
77	Endoscopic decompression of acute intestinal distension is associated with reduced mortality in critically ill patients. BMC Gastroenterology, 2020, 20, 87.	0.8	2
78	TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death and Disease, 2020, 11, 212.	2.7	90
79	The <i>PNPLA3</i> rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 1160-1168.	1.9	17
80	Genetic variants of UDPâ€glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary sclerosing cholangitis. Liver International, 2020, 40, 1645-1654.	1.9	2
81	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. Journal of Hepatology, 2020, 73, 540-548.	1.8	85
82	Secondary sclerosing cholangitis in critically ill patients has a poor outcome but lower tumour incidence than primary sclerosing cholangitis. United European Gastroenterology Journal, 2020, 8, 716-724.	1.6	13
83	Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure ofÂprevious direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). Zeitschrift Fur Gastroenterologie, 2020, 58, 841-846.	0.2	4
84	Viral eradication is required for sustained improvement of patientâ€reported outcomes in patients with hepatitis C. Liver International, 2019, 39, 54-59.	1.9	27
85	An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 192-199.e3.	2.4	16
86	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 781-793.	3.7	58
87	Systemic arterial blood pressure determines the therapeutic window of nonâ€selective beta blockers in decompensated cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 50, 696-706.	1.9	47
88	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scandinavian Journal of Gastroenterology, 2019, 54, 1033-1041.	0.6	13
89	Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis. PLoS ONE, 2019, 14, e0220666.	1.1	11
90	Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. Visceral Medicine, 2019, 35, 161-170.	0.5	52

#	Article	IF	CITATIONS
91	Dilatation Therapy and Demographic Characteristics Significantly Influence the Amount of Propofol for Therapeutic Endoscopic Retrograde Cholangiography. International Journal of Hepatology, 2019, 2019, 1-6.	0.4	0
92	Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. Journal of Hepatology, 2019, 71, 889-899.	1.8	52
93	Therapeutic plasma exchange in acute liver failure. Journal of Clinical Apheresis, 2019, 34, 589-597.	0.7	42
94	Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy. Frontiers in Immunology, 2019, 10, 2076.	2.2	11
95	Soluble immune markers in the different phases of chronic hepatitis B virus infection. Scientific Reports, 2019, 9, 14118.	1.6	14
96	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver International, 2019, 39, 714-726.	1.9	49
97	Transient increase of activated regulatory T cells early after kidney transplantation. Scientific Reports, 2019, 9, 1021.	1.6	25
98	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. Journal of Hepatology, 2019, 71, 673-684.	1.8	25
99	Effects of adenovirusâ€induced hepatocyte damage on chronic bile duct inflammation in a sclerosing cholangitis mouse model. Liver International, 2019, 39, 2330-2340.	1.9	2
100	Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. Journal of Autoimmunity, 2019, 103, 102289.	3.0	115
101	Tenâ€year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver International, 2019, 39, 1868-1875.	1.9	97
102	Endoscopic biliary drainage in patients with cholangiocarcinoma – self-expanding metal versus polyethylene stents. Scandinavian Journal of Gastroenterology, 2019, 54, 640-645.	0.6	3
103	Utility of viral kinetics in <scp>HCV</scp> therapy – It is not over until it is over?. Liver International, 2019, 39, 815-817.	1.9	3
104	Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease. European Journal of Gastroenterology and Hepatology, 2019, 31, 99-108.	0.8	3
105	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. Journal of Hepatology, 2019, 71, 301-312.	1.8	62
106	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. Viruses, 2019, 11, 275.	1.5	7
107	Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. The Lancet Gastroenterology and Hepatology, 2019, 4, 296-304.	3.7	23
108	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2068-2075.e2.	2.4	55

#	Article	IF	CITATIONS
109	Secondâ€line chemotherapy in biliary tract cancer: Outcome and prognostic factors. Liver International, 2019, 39, 914-923.	1.9	25
110	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infectious Diseases, The, 2019, 19, 275-286.	4.6	128
111	Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. PLoS ONE, 2019, 14, e0224751.	1.1	1
112	Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. JHEP Reports, 2019, 1, 437-445.	2.6	48
113	Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. Cancers, 2019, 11, 1904.	1.7	11
114	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. European Journal of Gastroenterology and Hepatology, 2019, 31, 1049-1056.	0.8	7
115	Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness. Clinical and Translational Gastroenterology, 2019, 10, e00066.	1.3	19
116	Quality of Life Is Associated With Wearable-Based Physical Activity in Patients With Inflammatory Bowel Disease: A Prospective, Observational Study. Clinical and Translational Gastroenterology, 2019, 10, e00094.	1.3	10
117	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology, 2019, 69, 684-698.	3.6	121
118	Recommendations on the Use of Magnetic Resonance Imaging for Collaborative Multicenter Studies in Primary Sclerosing Cholangitis. Hepatology, 2019, 69, 1358-1359.	3.6	7
119	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer, 2019, 8, 41-65.	4.2	38
120	Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis. Journal of Hepatology, 2019, 70, 722-734.	1.8	38
121	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. Journal of Hepatology, 2019, 70, 1008-1015.	1.8	90
122	Outcomes of renal dysfunction in patients with acute liver failure. United European Gastroenterology Journal, 2019, 7, 388-396.	1.6	16
123	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Journal of Hepatology, 2019, 70, 593-602.	1.8	20
124	SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. Journal of Hepatology, 2019, 70, 603-614.	1.8	9
125	Cholemic Nephropathy Causes Acute Kidney Injury and Is Accompanied by Loss of Aquaporin 2 in Collecting Ducts. Hepatology, 2019, 69, 2107-2119.	3.6	41
126	Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving directâ€acting antiviral treatment. Journal of Viral Hepatitis, 2019, 26, 224-230.	1.0	11

#	Article	IF	CITATIONS
127	Shear wave elastography prior to transjugular intrahepatic portosystemic shunt may predict the decrease in hepatic vein pressure gradient. Abdominal Radiology, 2019, 44, 1127-1134.	1.0	12
128	Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. European Radiology, 2019, 29, 1882-1892.	2.3	31
129	Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss. Journal of Infectious Diseases, 2018, 217, 1656-1666.	1.9	57
130	Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. United European Gastroenterology Journal, 2018, 6, 238-246.	1.6	17
131	Doseâ€dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver International, 2018, 38, 1602-1613.	1.9	33
132	Unmet needs and new models for future trials in autoimmune hepatitis. The Lancet Gastroenterology and Hepatology, 2018, 3, 363-370.	3.7	17
133	Autoimmune hepatitis. Nature Reviews Disease Primers, 2018, 4, 18017.	18.1	280
134	No cure for hepatitis B and D without targeting integrated viral DNA?. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 195-196.	8.2	15
135	Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis. Scientific Reports, 2018, 8, 419.	1.6	15
136	Systemic inflammation and immune cell phenotypes are associated with neuroâ€psychiatric symptoms in patients with chronic inflammatory liver diseases. Liver International, 2018, 38, 2317-2328.	1.9	9
137	The Role of Endoscopic Retrograde Cholangiopancreatography in the Diagnosis of Biliary Atresia: 14 Years' Experience. European Journal of Pediatric Surgery, 2018, 28, 261-267.	0.7	18
138	Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. Liver International, 2018, 38, 50-58.	1.9	72
139	Treatment of hepatitis C genotype 1Âinfection in Germany: effectiveness and safety of antiviral treatment in a realâ€world setting. United European Gastroenterology Journal, 2018, 6, 213-224.	1.6	22
140	Hepatitis E virus <scp>ORF</scp> 1 induces proliferative and functional T ell responses in patients with ongoing and resolved hepatitis E. Liver International, 2018, 38, 266-277.	1.9	18
141	Clinical and virological heterogeneity of hepatitis delta in different regions worldâ€wide: The Hepatitis Delta International Network (<scp>HDIN</scp>). Liver International, 2018, 38, 842-850.	1.9	72
142	Realâ€world effect of ribavirin on quality of life in <scp>HCV</scp> â€infected patients receiving interferonâ€free treatment. Liver International, 2018, 38, 834-841.	1.9	9
143	Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. Cancer Research, 2018, 78, 475-488.	0.4	61
144	Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?. Journal of Hepatology, 2018, 68, 851-853.	1.8	5

#	Article	IF	CITATIONS
145	Budesonide in Autoimmune Hepatitis: The Right Drug at the Right Time for the Right Patient. Clinical Gastroenterology and Hepatology, 2018, 16, 186-189.	2.4	17
146	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	6.1	42
147	IDDF2018-ABS-0113â€The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis. , 2018, , .		0
148	Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. Journal of Viral Hepatitis, 2018, 26, 466-475.	1.0	6
149	Editorial: "real world data―of AlH—time to connect!. Alimentary Pharmacology and Therapeutics, 2018, 48, 1315-1316.	1.9	1
150	Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. Scientific Reports, 2018, 8, 17452.	1.6	22
151	Clinical characteristics of patients with liver cirrhosis and spontaneous portosystemic shunts detected by ultrasound in a tertiary care and transplantation centre. Scandinavian Journal of Gastroenterology, 2018, 53, 1107-1113.	0.6	18
152	Longâ€term changes in liver elasticity in hepatitis C virusâ€infected patients with sustained virologic response after treatment with directâ€acting antivirals. United European Gastroenterology Journal, 2018, 6, 1188-1198.	1.6	23
153	Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites. Clinical and Translational Gastroenterology, 2018, 9, e189.	1.3	23
154	Novel therapeutic targets in autoimmune hepatitis. Journal of Autoimmunity, 2018, 95, 34-46.	3.0	28
155	Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts. United European Gastroenterology Journal, 2018, 6, 919-925.	1.6	17
156	Homologous recombination mediates stable Fah gene integration and phenotypic correction in tyrosinaemia mouse-model. World Journal of Hepatology, 2018, 10, 277-286.	0.8	10
157	Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice. Journal of Autoimmunity, 2018, 91, 83-96.	3.0	14
158	Restoration of mucosal integrity and epithelial transport function by concomitant anti-TNFα treatment in chronic DSS-induced colitis. Journal of Molecular Medicine, 2018, 96, 831-843.	1.7	9
159	BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection. PLoS ONE, 2018, 13, e0196977.	1.1	34
160	The Lancet–EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. Lancet, The, 2018, 392, 621-622.	6.3	19
161	Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. Journal of Hepatology, 2018, 69, 584-593.	1.8	95
162	Clinical significance of detectable and quantifiable <scp>HCV RNA</scp> at the end of treatment with ledipasvir/sofosbuvir in <scp>GT</scp> 1 patients. Liver International, 2018, 38, 1906-1910.	1.9	18

#	Article	IF	CITATIONS
163	Transjugular diagnostics in acute liver failure including measurements of hepatocentral venous biomarker gradients. Hepatology Research, 2018, 48, 914-925.	1.8	3
164	No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12†weeks in HCV DAA-experienced patients. Journal of Hepatology, 2018, 69, 1221-1230.	1.8	50
165	Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. Journal of Hepatology, 2018, 69, 982-984.	1.8	22
166	Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis. Oncotarget, 2018, 9, 17430-17442.	0.8	23
167	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Journal of Hepatology, 2018, 69, 896-904.	1.8	1,157
168	Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. Nature Communications, 2018, 9, 2275.	5.8	75
169	Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients. Journal of Infectious Diseases, 2018, 218, 1480-1484.	1.9	38
170	Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment. Journal of Medical Microbiology, 2018, 67, 1496-1508.	0.7	22
171	The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. Journal of Hepatology, 2017, 66, 1012-1021.	1.8	102
172	Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. Liver International, 2017, 37, 67-72.	1.9	6
173	A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. Antiviral Research, 2017, 141, 116-123.	1.9	9
174	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	0.6	355
175	Hepatitis C virus infection. Nature Reviews Disease Primers, 2017, 3, 17006.	18.1	354
176	Longâ€ŧerm outcome of chronic hepatitis C virus infection in a realâ€world setting: The German LOTOS study. Liver International, 2017, 37, 1468-1475.	1.9	8
177	Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral center. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1730-1738.	1.4	17
178	Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. Journal of Hepatology, 2017, 67, 480-489.	1.8	51
179	Patients with primary sclerosing cholangitis require more sedation during endoscopic retrograde cholangiography. Endoscopy International Open, 2017, 05, E315-E320.	0.9	1
180	Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2113-2121.	1.2	26

#	Article	IF	CITATIONS
181	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 549-558.	1.8	202
182	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. New England Journal of Medicine, 2017, 376, 2134-2146.	13.9	467
183	The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1347-1355.	1.2	28
184	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. Journal of Hepatology, 2017, 67, 237-245.	1.8	26
185	The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development. Journal of Autoimmunity, 2017, 78, 39-45.	3.0	24
186	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	9.4	230
187	Hepatitis D virus in Africa: several unmet needs. The Lancet Global Health, 2017, 5, e953-e954.	2.9	2
188	Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. Zeitschrift Fur Gastroenterologie, 2017, 55, 848-856.	0.2	16
189	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. Therapeutic Advances in Gastroenterology, 2017, 10, 609-618.	1.4	10
190	Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma – a case–control study. Scandinavian Journal of Gastroenterology, 2017, 52, 1398-1406.	0.6	1
191	Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antiviral Research, 2017, 147, 19-28.	1.9	28
192	Risk estimation for biliary tract cancer: Development and validation of a prognostic score. Liver International, 2017, 37, 1852-1860.	1.9	21
193	Hepatic Amiodarone Lipotoxicity Is Ameliorated by Genetic and Pharmacological Inhibition of Endoplasmatic Reticulum Stress. Toxicological Sciences, 2017, 159, 402-412.	1.4	10
194	Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations. Molecular Therapy, 2017, 25, 2533-2545.	3.7	8
195	Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia. American Journal of Hematology, 2017, 92, E641-E644.	2.0	17
196	Silymarin for Treatment of Nonalcoholic Steatohepatitis–A New Kid on the Block?. Clinical Gastroenterology and Hepatology, 2017, 15, 1863-1865.	2.4	0
197	Increased apoptosis of regulatory T cells in patients with active autoimmune hepatitis. Cell Death and Disease, 2017, 8, 3219.	2.7	22
198	Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Human Vaccines and Immunotherapeutics, 2017, 13, 2931-2952.	1.4	14

#	Article	IF	CITATIONS
199	A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin. United European Gastroenterology Journal, 2017, 5, 668-676.	1.6	23
200	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infectious Diseases, The, 2017, 17, 215-222.	4.6	109
201	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus–Specific T Cells. Journal of Infectious Diseases, 2017, 215, 139-149.	1.9	32
202	Treatment With Ledipasvir–Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection. Annals of Internal Medicine, 2017, 166, 109.	2.0	164
203	Antiviral treatment and liverâ€related complications in hepatitis delta. Hepatology, 2017, 65, 414-425.	3.6	88
204	Nonâ€invasive fibrosis score for hepatitis delta. Liver International, 2017, 37, 196-204.	1.9	42
205	Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. Scandinavian Journal of Gastroenterology, 2017, 52, 116-124.	0.6	13
206	Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections. Frontiers in Immunology, 2017, 8, 525.	2.2	25
207	Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. PLoS ONE, 2017, 12, e0179074.	1.1	33
208	Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw572.	1.3	1
209	Therapy preferences of patients with lung and colon cancer: a discrete choice experiment. Patient Preference and Adherence, 2017, Volume 11, 1647-1656.	0.8	18
210	Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy. PLoS ONE, 2017, 12, e0181107.	1.1	33
211	Safety and efficacy of chemosaturation in patients with primary and secondary liver tumours: A single-centre experience after 54 treatments Journal of Clinical Oncology, 2017, 35, e15625-e15625.	0.8	0
212	Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience. Journal of Transplantation, 2016, 2016, 1-22.	0.3	3
213	Application of the Liver Maximum Function Capacity Test in Acute Liver Failure: A Helpful Tool for Decision-Making in Liver Transplantation?. Case Reports in Transplantation, 2016, 2016, 1-5.	0.1	1
214	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. PLoS ONE, 2016, 11, e0168544.	1.1	2
215	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2016, 14, 1821-1830.e6.	2.4	61
216	Preferential accumulation of T helper cells but not cytotoxic T cells characterizes benign subclinical rejection of human liver allografts. Liver Transplantation, 2016, 22, 943-955.	1.3	25

#	Article	IF	CITATIONS
217	Nonreversible MAIT cellâ€dysfunction in chronic hepatitis C virus infection despite successful interferonâ€free therapy. European Journal of Immunology, 2016, 46, 2204-2210.	1.6	142
218	Daclatasvir plus asunaprevir for <scp>HCV</scp> genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver International, 2016, 36, 954-962.	1.9	14
219	Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. Gut, 2016, 65, 1015-1023.	6.1	7
220	MicroRNA-125b-5p mimic inhibits acute liver failure. Nature Communications, 2016, 7, 11916.	5.8	42
221	Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. Liver Transplantation, 2016, 22, 42-52.	1.3	111
222	Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes InÂVivo Attenuates Liver Fibrosis. Cell Stem Cell, 2016, 18, 797-808.	5.2	181
223	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. Journal of Hepatology, 2016, 65, 473-482.	1.8	64
224	Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. Journal of Clinical Virology, 2016, 80, 1-7.	1.6	13
225	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut, 2016, 65, 1733-1743.	6.1	145
226	Direct-Acting Antiviral–Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. Journal of Infectious Diseases, 2016, 214, 1965-1974.	1.9	127
227	Hepatitis C: individualised medicine versus one pill fits all. The Lancet Gastroenterology and Hepatology, 2016, 1, 86-87.	3.7	5
228	Cutting edge issues in autoimmune hepatitis. Journal of Autoimmunity, 2016, 75, 6-19.	3.0	96
229	Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. Cancer Cell, 2016, 30, 308-323.	7.7	68
230	Scientific Panel for Health: better research for better health. Lancet, The, 2016, 388, 865-866.	6.3	8
231	Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8ÂT Cell Responses against Cancer. Cell Reports, 2016, 17, 2234-2246.	2.9	57
232	No Evidence That Azathioprine Increases Risk ofÂCholangiocarcinoma in Patients With Primary SclerosingÂCholangitis. Clinical Gastroenterology and Hepatology, 2016, 14, 1806-1812.	2.4	15
233	Future landscape of hepatitis C research – Basic, translational and clinical perspectives. Journal of Hepatology, 2016, 65, S143-S155.	1.8	26
234	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Clinical Infectious Diseases, 2016, 63, 776-783.	2.9	45

#	Article	IF	CITATIONS
235	Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. Gastroenterology, 2016, 151, 338-350.e7.	0.6	65
236	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 685-697.	4.6	402
237	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical Infectious Diseases, 2016, 62, 1228-1234.	2.9	23
238	Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clinical Infectious Diseases, 2016, 62, 561-567.	2.9	89
239	Host cell mTORC1 is required for HCV RNA replication. Gut, 2016, 65, 2017-2028.	6.1	47
240	Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. Drugs in Context, 2016, 5, 1-9.	1.0	4
241	Treatment strategies in patients with hepatocellular carcinoma in a real-life cohort Journal of Clinical Oncology, 2016, 34, e15630-e15630.	0.8	0
242	Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells. Antiviral Research, 2015, 124, 122-131.	1.9	5
243	The BH3â€only protein BID impairs the p38â€mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice. Hepatology, 2015, 62, 816-828.	3.6	9
244	Prediction of short―and longâ€ŧerm outcome in patients with autoimmune hepatitis. Hepatology, 2015, 62, 1524-1535.	3.6	115
245	Regional differences in health care of patients with inflammatory bowel disease in Germany. Health Economics Review, 2015, 5, 29.	0.8	7
246	Longâ€ŧerm outcome of liver transplant patients with Budd hiari syndrome secondary to myeloproliferative neoplasms. Liver International, 2015, 35, 2042-2049.	1.9	35
247	Liver transplantation for critically III patients with secondary sclerosing cholangitis: Outcome and complications. Liver Transplantation, 2015, 21, 1295-1299.	1.3	18
248	Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. Frontiers in Immunology, 2015, 6, 270.	2.2	27
249	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. PLoS ONE, 2015, 10, e0128069.	1.1	5
250	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. PLoS ONE, 2015, 10, e0140525.	1.1	8
251	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS ONE, 2015, 10, e0145622.	1.1	2
252	Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. Clinical Gastroenterology and Hepatology, 2015, 13, 2342-2349.e2.	2.4	57

#	Article	IF	CITATIONS
253	Gray scale and contrastâ€enhanced ultrasound imaging of malignant liver tumors of vascular origin. United European Gastroenterology Journal, 2015, 3, 63-71.	1.6	13
254	Altered effector functions of NK cells in chronic hepatitis C are associated with <i>IFNL3</i> polymorphism. Journal of Leukocyte Biology, 2015, 98, 283-294.	1.5	11
255	Eligibility and safety of the first interferonâ€free therapy against hepatitis C in a realâ€world setting. Liver International, 2015, 35, 1845-1852.	1.9	25
256	Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8 ⁺ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. Journal of Virology, 2015, 89, 8304-8317.	1.5	32
257	Cholangiocarcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 219.	1.0	0
258	Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 285-294.e1.	2.3	5
259	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. Molecular Therapy, 2015, 23, 1630-1640.	3.7	165
260	Autoimmune hepatitis – Update 2015. Journal of Hepatology, 2015, 62, S100-S111.	1.8	290
261	Microbiological analysis of bile and its impact in critically ill patients with secondary sclerosing cholangitis. Journal of Infection, 2015, 70, 483-490.	1.7	31
262	Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals. Gut, 2015, 64, 469-482.	6.1	51
263	Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report. BMC Gastroenterology, 2015, 15, 60.	0.8	42
264	An Unusual Cause of Chronic Diarrhea Treated by Interventional Radiology. Gastroenterology, 2015, 149, 1339-1340.	0.6	0
265	Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. Gastroenterology, 2015, 149, 1345-1360.	0.6	306
266	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology, 2015, 148, 108-117.	0.6	317
267	Autoimmune hepatitis in a murine autoimmune polyendocrine syndrome type 1 model is directed against multiple autoantigens. Hepatology, 2015, 61, 1295-1305.	3.6	32
268	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. Journal of Hepatology, 2015, 62, 41-47.	1.8	59
269	MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells. Journal of Hepatology, 2015, 62, 101-110.	1.8	35
270	New kids on the block—step by step to an ideal HCV therapy. Lancet, The, 2015, 385, 1050-1052.	6.3	10

#	Article	IF	CITATIONS
271	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. Journal of Hepatology, 2015, 62, 31-40.	1.8	50
272	Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. PLoS ONE, 2015, 10, e0134839.	1.1	3
273	MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma. PLoS ONE, 2015, 10, e0139305.	1.1	88
274	Increased HEV Seroprevalence in Patients with Autoimmune Hepatitis. PLoS ONE, 2014, 9, e85330.	1.1	61
275	Short-Term Regulation of Murine Colonic NBCe1-B (Electrogenic Na+/HCO3â^ Cotransporter) Membrane Expression and Activity by Protein Kinase C. PLoS ONE, 2014, 9, e92275.	1.1	7
276	Explanted Diseased Livers – A Possible Source of Metabolic Competent Primary Human Hepatocytes. PLoS ONE, 2014, 9, e101386.	1.1	55
277	Treatment of NaÃ ⁻ ve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. PLoS ONE, 2014, 9, e108751.	1.1	15
278	p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury. Gut, 2014, 63, 1501-1512.	6.1	45
279	Treatment of autoimmune hepatitis. Clinical Liver Disease, 2014, 3, 15-17.	1.0	4
280	Overall safety profile of boceprevir plus peginterferon alfaâ€⊉b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver International, 2014, 34, 707-719.	1.9	15
281	The impact of hepatitis E in the liver transplant setting. Journal of Hepatology, 2014, 61, 1418-1429.	1.8	115
282	Changes in liver stiffness using acoustic radiation force impulse imaging in patients with obstructive cholestasis and cholangitis. Digestive and Liver Disease, 2014, 46, 625-631.	0.4	28
283	The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. Journal of Antimicrobial Chemotherapy, 2014, 69, 2123-2131.	1.3	159
284	The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. Gastroenterology, 2014, 147, 366-376.e6.	0.6	38
285	A Mutation in the Hepatitis E Virus RNA Polymerase Promotes Its Replication and Associates With Ribavirin Treatment Failure in Organ Transplant Recipients. Gastroenterology, 2014, 147, 1008-1011.e7.	0.6	171
286	Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data. Oncologist, 2014, 19, 1156-1168.	1.9	90
287	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet, The, 2014, 384, 1597-1605.	6.3	316
288	HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. Lancet Infectious Diseases, The, 2014, 14, 678-679.	4.6	73

#	Article	IF	CITATIONS
289	Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1733-1738.	2.4	66
290	Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2014, 384, 414-426.	6.3	376
291	Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. Journal of Hepatology, 2014, 61, 1106-1114.	1.8	119
292	An Extended ΔCT-Method Facilitating Normalisation with Multiple Reference Genes Suited for Quantitative RT-PCR Analyses of Human Hepatocyte-Like Cells. PLoS ONE, 2014, 9, e93031.	1.1	54
293	PEC-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C. PLoS ONE, 2014, 9, e94512.	1.1	17
294	Angiopoietin-2 and Biliary Diseases: Elevated Serum, but Not Bile Levels Are Associated with Cholangiocarcinoma. PLoS ONE, 2014, 9, e97046.	1.1	23
295	Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. PLoS ONE, 2014, 9, e101002.	1.1	50
296	Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. PLoS ONE, 2014, 9, e110857.	1.1	15
297	Novel therapies for hepatitis C — one pill fits all?. Nature Reviews Drug Discovery, 2013, 12, 595-610.	21.5	174
298	Optimal treatment with boceprevir for chronic HCV infection. Liver International, 2013, 33, 14-22.	1.9	9
299	Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4 ⁺ T cells. Hepatology, 2013, 58, 718-728.	3.6	74
300	Sofosbuvir: the final nail in the coffin for hepatitis C?. Lancet Infectious Diseases, The, 2013, 13, 378-379.	4.6	33
301	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infectious Diseases, The, 2013, 13, 497-506.	4.6	84
302	Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. Journal of Lipid Research, 2013, 54, 2195-2205.	2.0	40
303	Immunoglobulin G4-associated cholangitis: Dominating immunoglobulin G4-positive clones within the B-cell receptor repertoire indicate light at the end of a long tunnel. Hepatology, 2013, 57, 2110-2113.	3.6	4
304	Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. PLoS ONE, 2013, 8, e55285.	1.1	91
305	Liver Cirrhosis, Transplantation and Organ Shortage. Deutsches Ärzteblatt International, 2013, 110, 83-4.	0.6	17
306	Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opinion on Drug Safety, 2012, 11, 361-368.	1.0	53

#	Article	IF	CITATIONS
307	High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis. Journal of Hepatology, 2012, 56, 1063-1069.	1.8	35
308	Telaprevir and Boceprevir: The Future Is Now. Current Hepatitis Reports, 2012, 11, 160-171.	0.3	2
309	Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naÃ ⁻ ve patients with chronic hepatitis C: A randomized phase II study. Hepatology, 2012, 56, 884-893.	3.6	52
310	Update on the Management of HBV-HDV Coinfection. Current Hepatitis Reports, 2012, 11, 95-101.	0.3	0
311	Phase III results of Boceprevir in treatment naÃ ⁻ ve patients with chronic hepatitis C genotype 1. Liver International, 2012, 32, 27-31.	1.9	32
312	Second-wave Protease Inhibitors: Choosing an Heir. Clinics in Liver Disease, 2011, 15, 597-609.	1.0	27
313	Therapeutic Strategies for Autoimmune Hepatitis. Digestive Diseases, 2011, 29, 411-415.	0.8	12
314	Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. Journal of Autoimmunity, 2011, 37, 242-253.	3.0	48
315	Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. Journal of Hepatology, 2011, 54, 1114-1122.	1.8	105
316	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. Journal of Hepatology, 2011, 55, 554-563.	1.8	47
317	Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial. Antiviral Therapy, 2011, 16, 1021-1033.	0.6	59
318	Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology, 2011, 53, 875-884.	3.6	143
319	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology, 2011, 54, 1947-1955.	3.6	255
320	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. Journal of Virology, 2011, 85, 7613-7621.	1.5	40
321	Republished paper: Managing HBV in patients with impaired immunity. Postgraduate Medical Journal, 2011, 87, 223-238.	0.9	3
322	Plasma bile acids are not associated with energy metabolism in humans. Nutrition and Metabolism, 2010, 7, 73.	1.3	67
323	Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, 51, 2193-2213.	3.6	1,243
324	Treatment of HBV/HCV coinfection. Expert Opinion on Pharmacotherapy, 2010, 11, 919-928.	0.9	38

#	Article	IF	CITATIONS
325	Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis. Gastroenterology, 2010, 139, 58-72.e4.	0.6	252
326	Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis. Gastroenterology, 2010, 139, 1198-1206.	0.6	394
327	SLA/LP/tRNP(Ser)Sec antigen in autoimmune hepatitis: Identification of the native protein in human hepatic cell extract. Journal of Autoimmunity, 2010, 34, 59-65.	3.0	24
328	Autoimmune Hepatitis. Seminars in Liver Disease, 2009, 29, 239-240.	1.8	15
329	Prof. Daniel Shouval. Journal of Hepatology, 2009, 51, 620-622.	1.8	0
330	Na+/H+ exchanger isoform NHE3 and NHERF adaptor protein expression, localization and function in the small and large intestine of CD45RB high transfer colitis. FASEB Journal, 2009, 23, 570.9.	0.2	0
331	Dual role of the Na+/H+ exchanger isoform 3 for PEPT1â€mediated H+/dipeptide cotransport in native murine intestine. FASEB Journal, 2009, 23, 796.42.	0.2	0
332	Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. Journal of Experimental Medicine, 2008, 205, 1409-1422.	4.2	173
333	Characterization, Outcome, and Prognosis in 273 Patients with Primary Sclerosing Cholangitis: A Single Center Study. American Journal of Gastroenterology, 2007, 102, 107-114.	0.2	353
334	The way forward in HCV treatment — finding the right path. Nature Reviews Drug Discovery, 2007, 6, 991-1000.	21.5	267
335	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon-α2b therapy for Acute Hepatitis C. Antiviral Therapy, 2007, 12, 303-316.	0.6	22
336	Present and future therapy for hepatitis C virus. Expert Review of Anti-Infective Therapy, 2006, 4, 781-793.	2.0	11
337	Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2006, 41, 1227-1234.	0.6	46
338	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. Hepatology, 2006, 43, 250-256.	3.6	229
339	Autoimmune hepatitis, from mechanisms to therapy. Hepatology, 2006, 43, S132-S144.	3.6	159
340	Reply:. Hepatology, 2006, 44, 511-512.	3.6	2
341	Future trends in hepatitis C therapy. Future Virology, 2006, 1, 99-107.	0.9	3
342	New Diagnostic Technology in Liver Disease. Seminars in Liver Disease, 2006, 26, 307-308.	1.8	0

#	Article	IF	CITATIONS
343	The Role of Stem Cells in Physiology, Pathophysiology, and Therapy of the Liver. Stem Cell Reviews and Reports, 2006, 2, 51-58.	5.6	1
344	Autoimmune hepatitis. Current Gastroenterology Reports, 2005, 7, 81-83.	1.1	33
345	Treatment of chronic HCV infection in compensated and decompensated cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, S94-S98.	1.4	0
346	Acute hepatitis C infection: Can immunology teach us the right way to treat?. Current Hepatitis Reports, 2004, 3, 148-156.	0.3	3
347	Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterology Clinics of North America, 2004, 33, 11-24.	1.0	24
348	Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transplantation, 2003, 9, 191-196.	1.3	44
349	Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. Current Hepatitis Reports, 2003, 2, 24-31.	0.3	1
350	Autoimmune hepatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 291-306.	1.0	9
351	Hepatic amino-acid metabolism in liver cirrhosis and in the long-term course after liver transplantation. Transplant International, 2003, 16, 1-8.	0.8	22
352	A comparison of fibrosis progression in chronic liver diseases. Journal of Hepatology, 2003, 38, 257-265.	1.8	401
353	Current State of Interferon Therapy in the Treatment of Chronic Hepatitis B. Seminars in Liver Disease, 2002, 22, 007-014.	1.8	32
354	Autoimmunity and viruses. Clinics in Liver Disease, 2002, 6, 739-753.	1.0	23
355	Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Current Gastroenterology Reports, 2002, 4, 23-30.	1.1	82
356	Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology, 2002, 35, 126-131.	3.6	231
357	Autoimmune hepatitis: Clinical challenges. Gastroenterology, 2001, 120, 1502-1517.	0.6	210
358	Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, The, 2001, 358, 958-965.	6.3	5,888
359	Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study. Transplant Infectious Disease, 2001, 3, 16-23.	0.7	29
360	Soluble liver antigen: Isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology, 2001, 33, 591-596.	3.6	63

#	Article	IF	CITATIONS
361	Decreased splanchnic oxygen uptake and increased systemic oxygen uptake in cirrhosis are normalized after liver transplantation. Liver Transplantation, 2001, 7, 1015-1022.	1.3	12
362	Ras adenoviruses modulate cyclin E protein expression and DNA synthesis after partial hepatectomy. Oncogene, 2001, 20, 5264-5278.	2.6	23
363	Involvement of Proteasome α-Subunit PSMA7 in Hepatitis C Virus Internal Ribosome Entry Site-Mediated Translation. Molecular and Cellular Biology, 2001, 21, 8357-8364.	1.1	63
364	Hepatitis C and autoimmune hepatitis. Hepatology, 2000, 31, 811-812.	3.6	8
365	Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver International, 2000, 20, 312-318.	1.9	61
366	Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature Medicine, 2000, 6, 578-582.	15.2	697
367	lκBα gene therapy in tumor necrosis factor-α- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Therapy, 2000, 7, 1315-1323.	2.2	22
368	Hyperstimulation With Interleukin 6 Inhibits Cell Cycle Progression After Hepatectomy in Mice. Hepatology, 2000, 32, 514-522.	3.6	111
369	Recurrent Autoimmune Hepatitis After Liver Transplantation—When Non-self Becomes Self. Hepatology, 2000, 32, 868-870.	3.6	75
370	Autoimmunity in Liver Diseases. Clinical Reviews in Allergy and Immunology, 2000, 18, 127-140.	2.9	36
371	Autoimmune Polyglandular Syndrome Type 1. Clinical Reviews in Allergy and Immunology, 2000, 18, 167-184.	2.9	25
372	Target Proteins in Human Autoimmunity: Cytochromes P450 and Udp-Glycoronosyltransferases. Canadian Journal of Gastroenterology & Hepatology, 2000, 14, 429-439.	1.8	46
373	lκBα gene therapy in tumor necrosis factor-α- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Therapy, 2000, 7, 1315-1323.	2.2	13
374	Regulation of cytosolic free calcium concentration by extracellular nucleotides in human hepatocytes. American Journal of Physiology - Renal Physiology, 1999, 276, G164-G172.	1.6	33
375	Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation. Hepatology, 1999, 30, 244-256.	3.6	125
376	The Pre-S region determines the intracellular localization and appearance of hepatitis B virus. Hepatology, 1999, 30, 517-525.	3.6	52
377	Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rats. Hepatology, 1999, 30, 1159-1166.	3.6	72
378	Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. Journal of Hepatology, 1999, 31, 39-42.	1.8	170

#	Article	IF	CITATIONS
379	Lipid Evaluation in HIV-1-Positive Patients Treated with Protease Inhibitors. Antiviral Therapy, 1999, 4, 163-170.	0.6	33
380	Antiâ€nuclear and antiâ€histone autoâ€antibodies in autoimmune disease. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 453-456.	1.4	0
381	Morphological and molecular characterization of human gastric mucous cells in long-term primary culture. Pflugers Archiv European Journal of Physiology, 1998, 436, 871-881.	1.3	10
382	Recent developments in autoimmune liver diseases. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, S256-S271.	1.4	17
383	Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. Journal of Gastroenterology, 1997, 32, 480-486.	2.3	61
384	Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. Digestive Diseases and Sciences, 1996, 41, 27S-40S.	1.1	28
385	Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transplantation, 1996, 2, 253-262.	1.9	87
386	Cytochrome P450 enzymes and UDP-Glucuronosyltransferases as hepatocellular autoantigens. Molecular Biology Reports, 1996, 23, 235-242.	1.0	10
387	M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epiphenomena?. Hepatology, 1992, 16, 1128-1136.	3.6	67
388	M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epiphenomena?. Hepatology, 1992, 16, 1128-1136.	3.6	10